Therapeutic options in the management of renal cell carcinoma
- 1 June 2002
- journal article
- review article
- Published by Elsevier in Seminars in Oncology
- Vol. 29 (3) , 41-46
- https://doi.org/10.1053/sonc.2002.33083
Abstract
No abstract availableKeywords
This publication has 35 references indexed in Scilit:
- Outpatient treatment with subcutaneous histamine dihydrochloride in combination with interleukin-2 and interferon-α in patients with metastatic renal cell carcinoma: results of an open single-armed multicentre phase II studyAnnals of Oncology, 2002
- Results From a Randomized Phase III Study Comparing Combined Treatment With Histamine Dihydrochloride Plus Interleukin-2 Versus Interleukin-2 Alone in Patients With Metastatic MelanomaJournal of Clinical Oncology, 2002
- Oxaliplatin, 5-Fluorouracil, and Folinic Acid (Folfox) in Patients With Metastatic Renal Cell CarcinomaAmerican Journal of Clinical Oncology, 2000
- SYSTEMIC THERAPY FOR RENAL CELL CARCINOMAJournal of Urology, 2000
- Cancer statistics, 1999CA: A Cancer Journal for Clinicians, 1999
- In vivo trafficking of adoptively transferred interleukin-2 expanded tumor-infiltrating lymphocytes and peripheral blood lymphocytes. Results of a double gene marking trial.Journal of Clinical Investigation, 1996
- Home therapy with recombinant interleukin-2 and interferon-$alpha;2b in advanced human malignanciesThe Lancet, 1990
- Postoperative radiotherapy in stage II and III renal adenocarcinoma. A randomized trial by the Copenhagen renal cancer study groupInternational Journal of Radiation Oncology*Biology*Physics, 1987
- Observations on the Systemic Administration of Autologous Lymphokine-Activated Killer Cells and Recombinant Interleukin-2 to Patients with Metastatic CancerNew England Journal of Medicine, 1985
- Response of renal adenocarcinoma to cyclophosphamideUrology, 1975